Samanta Cimitan Appointed Chief Executive Officer (CEO) at Celonic

09-Aug-2023 - Celonic Group has appointed Dr. Samanta Cimitan as the Chief Executive Officer (CEO) of the Celonic Group, a subsidiary of the independent and privately owned J.RETTENMAIER & Söhne Company (JRS Group). Samanta succeeds Dr. Konstantin Matentzoglu, who will step down after 9 years as CEO. During ...

MIMETAS Elected Most Innovative Company of the Netherlands

04-Nov-2022 - MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position. Henk Volberda, chairman of the jury ...

Targeted drug delivery without the normal side effects

Indo-Irish Biotech Startup Secures Funding to Accelerate Cancer and Rare Genetic Disease Therapy

09-Jun-2021 - CyGenica has announced that it has raised USD $1.4 million in a seed fund investment round, led by global venture capital investor SOSV. The funding round will accelerate validation of CyGenica’s proprietary technology which enables safe, targeted and affordable intercellular drug ...

Cellbox Solutions Appoints Dr. Herbert Mueller-Hartmann as Head of Research and Development

08-Jun-2020 - Cellbox Solutions GmbH announces the appointment of former Head of Biosolutions R&D from Lonza Pharma and Biotech, Dr. Herbert A. Mueller-Hartmann, as the new Head of Research and Development. Dr. Mueller-Hartmann will be continuing on the successful work of Dr. Hans-Otto Nagels. Wolfgang ...

Vetter Works Towards a Sustainable Energy Supply

All German sites of the pharmaceutical service provider will be supplied with green electricity moving forward

31-May-2019 - Vetter has reached another important milestone regarding sustainability. Beginning immediately, all German sites of the company will be supplied with only CO2 neutral energy from certified renewable energy sources. This action underlines the CDMO’s commitment to climate and environmental ...

Potential New Treatment for Heart Attack

Prospective drug found by testing in human heart muscle grown from stem cells

11-Mar-2019 - Domainex announced that a team of its scientists, working in close partnership with Professor Michael Schneider and his team at Imperial College, have found a potential new drug candidate for treating the heart damage caused during a heart attack by targeting the way the heart reacts to stress, ...

CiMaas and PharmaCell Enter a Collaborative Agreement

14-Jul-2015 - CiMaas BV and PharmaCell BV have agreed to collaborate in the clinical development of CiMaas’ products. Under the agreement, PharmaCell will provide consulting services on writing GMP-compliant documents for the purpose of translating the CiMaas cell therapy processes into GMP. Options have been ...

Amarna Therapeutics Teaming Up with Austrian CBmed in the Development of Immunotherapies

01-Jul-2015 - DutchAmarna Therapeutics announced that it has entered into a cooperation with Austrian Center for Biomarker Research in Medicine (CBmed), for the development of immunotherapies against acute lymphoblastic leukemia (ALL), obesity, diabetes mellitus type 2 (DM2) and atherosclerotic cardiovascular ...

AYOXXA and Grünenthal Completed Research Collaboration

25-Jun-2015 - AYOXXA Biosystems and Grünenthal have completed a first research collaboration to validate detection limits for a biomarker based on AYOXXA’s innovative proprietary technology platform. The focus of this study was to analyze an inflammation marker at very low concentrations released from human ...

Deuterium in Living Organisms May Provide Clues to Prevent and Treat Cancer

19-Jun-2015 - Sub-molecular cellular events, driven by hydrogen’s replacements with deuterium, explain medical and economical failures of targeted molecular cancer drugs, which are the main conclusions of the 3 rd International Congress on Deuterium Depletion held in Budapest, Hungary, in May 2015. The ...